• NEJM publishes second successful Epidiolex trial in LGS pharmatimes
    May 24, 2018
    In the trial - the first dose-ranging study to compare cannabidiol to placebo as add-on therapy in LGS - both doses of Epidiolex significantly reduced drop seizure frequency in patients with poor seizure control despite the use of multiple anti-epileptic
PharmaSources Customer Service